Curis Hedgehog and Beyond --plus multi-targeting cancer inhibitors

Ovarian Cancer

Roche has informed Curis that preliminary findings from the primary analysis of the study warrant additional investigation to clarify and interpret potential clinical activity of the drug candidate observed in this trial. Accordingly, Roche and Genentech have indicated that they plan to further analyze the data, including subset analyses in the coming months. Following these analyses, they expect to make a portfolio decision regarding whether, or to what extent, they will continue development of GDC-0449 in advanced ovarian cancer.

No obvious new safety signals were observed in patients treated with GDC-0449. It is expected that data from this Phase II study will be submitted for presentation at an upcoming medical meeting.

http://phx.corporate-ir.net/phoenix.zht ... highlight=

Colon Cancer

Roche has informed Curis that the trial did not meet its primary endpoint of extending the time from randomization to disease progression or death in study patients who received GDC-0449 in addition to the current standard of care of bevacizumab and chemotherapy when compared to those patients that received only the current standard of care treatment. GDC-0449 is being developed by Roche and Genentech under a collaboration agreement between Curis and Genentech. It is expected that data from the Phase II study will be submitted for presentation at a future medical meeting.

http://phx.corporate-ir.net/phoenix.zht ... highlight=

Metastatic Colorectal Cancer
Jordan Berlin, MD: What is the hedgehog protein pathway and current GDC0049 trail results? Dr. Berlin is the Clinical Director, Gastrointestinal Oncology, Vanderbilt University.
http://www.youtube.com/watch?v=sEJnaaTrWd0